Holen Sie sich die Stockscreener-App
14.25
1.06%
0.15
Schlusskurs vom Vortag:
$14.10
Offen:
$14.07
24-Stunden-Volumen:
132.98K
Relative Volume:
0.80
Marktkapitalisierung:
$965.69M
Einnahmen:
$-9,000
Nettoeinkommen (Verlust:
$-68.03M
KGV:
-13.57
EPS:
-1.05
Netto-Cashflow:
$-44.76M
1W Leistung:
-1.66%
1M Leistung:
+0.14%
6M Leistung:
-9.35%
1J Leistung:
-19.22%
1-Tages-Spanne:
$13.94
$14.56
1-Wochen-Bereich:
$13.81
$14.79
52-Wochen-Spanne:
$12.56
$25.00
Pulse Biosciences Inc Stock (PLSE) Company Profile
Firmenname
Pulse Biosciences Inc
Sektor
Telefon
510-906-4600
Adresse
3957 POINT EDEN WAY, HAYWARD, CA
Vergleichen Sie PLSE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
14.25 | 955.52M | -9,000 | -68.03M | -44.76M | -1.05 |
|
ISRG
Intuitive Surgical Inc
|
535.00 | 191.90B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
207.11 | 59.36B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
79.00 | 39.13B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
257.58 | 38.05B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
44.12 | 33.62B | 27.43B | 1.27B | 1.01B | 1.5829 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-07 | Eingeleitet | Oppenheimer | Outperform |
| 2021-07-27 | Eingeleitet | Stephens | Overweight |
| 2021-03-11 | Eingeleitet | Maxim Group | Buy |
| 2021-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-12 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Pulse Biosciences Inc Aktie (PLSE) Neueste Nachrichten
Trading the Move, Not the Narrative: (PLSE) Edition - Stock Traders Daily
Dividend Watch: Is Pulse Biosciences Inc stock influenced by commodity pricesJuly 2025 Breakouts & AI Driven Price Forecasts - baoquankhu1.vn
Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 1.4%Here's What Happened - MarketBeat
Pulse Biosciences Nabs FDA IDE Approval for nPulse Cardiac Catheter Ablation System Study - Medical Product Outsourcing
Pulse Biosciences updates investor deck on cardiac pipeline - TipRanks
Pulse Biosciences, Inc. Updates Investor Presentation - TradingView — Track All Markets
Earnings Miss: Is Pulse Biosciences Inc. exposed to currency risksWeekly Stock Report & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Analyst Calls: Is Pulse Biosciences Inc stock recession proof2025 Earnings Impact & Daily Profit Focused Screening - Bộ Nội Vụ
Pulse Biosciences, Inc (PLSE) Stock Analysis: Exploring A 51% Potential Upside - DirectorsTalk Interviews
New Cardiac Ablation Data and Board Appointment Might Change The Case For Investing In Pulse Biosciences (PLSE) - simplywall.st
How Investors May Respond To Pulse Biosciences (PLSE) AF Data Reveal And Boardroom Refresh - Yahoo Finance
How buybacks impact Pulse Biosciences Inc. stock valueEarnings Recap Summary & Free Verified High Yield Trade Plans - Улправда
Will Pulse Biosciences Inc. stock outperform tech sector in 20252025 Geopolitical Influence & Verified Trade Idea Suggestions - Улправда
Will Pulse Biosciences Inc. (6L8) stock profit from automation wave2025 Key Highlights & Entry Point Confirmation Signals - ulpravda.ru
Pulse Biosciences appoints healthcare veteran Maria Sainz to board By Investing.com - Investing.com Nigeria
Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors - 01net
Pulse Biosciences Adds Veteran Healthtech Leader to Board - TipRanks
Pulse Biosciences Elects Maria Sainz to Board of Directors - TradingView — Track All Markets
Pulse Biosciences appoints healthcare veteran Maria Sainz to board - Investing.com
Can Pulse Biosciences Inc. stock continue upward trendPortfolio Performance Summary & Growth Focused Entry Reports - ulpravda.ru
Weekly Earnings: Will Pulse Biosciences Inc. (6L8) stock outperform value peersEarnings Overview Summary & Growth Focused Entry Reports - Улправда
Will Pulse Biosciences Inc. stock reach Wall Street targetsMarket Trend Review & Real-Time Volume Trigger Notifications - Улправда
Is MBX Biosciences Inc. stock positioned well for digital economyJuly 2025 Short Interest & Safe Entry Momentum Tips - Улправда
Why Pulse Biosciences Inc. stock remains resilient2025 Key Lessons & Daily Stock Momentum Reports - Улправда
Can Pulse Biosciences Inc. (6L8) stock deliver double digit returnsMarket Weekly Review & Safe Capital Allocation Plans - Улправда
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium - Bluefield Daily Telegraph
(PLSE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Working capital per share of Pulse Biosciences, Inc. – DUS:6L8 - TradingView — Track All Markets
What analysts say about Pulse Biosciences Inc 6L8 stockEarnings Growth Projections & Test Our Stock Screener — Free Forever - Early Times
Value Recap: Is The E.W. Scripps Company stock a buy in volatile marketsLong Setup & Daily Market Momentum Tracking - moha.gov.vn
Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Bluefield Daily Telegraph
Total debt per share of Pulse Biosciences, Inc. – MUN:6L8 - TradingView — Track All Markets
Positron (OTCMKTS:POSC) vs. Pulse Biosciences (NASDAQ:PLSE) Critical Comparison - Defense World
What drives Pulse Biosciences Inc 6L8 stock priceHigh Dividend Yield Stocks & High Profit Market Growth - earlytimes.in
MSN Money - MSN
Understanding the Setup: (PLSE) and Scalable Risk - Stock Traders Daily
Pulse Biosciences (PLSE): Valuation Check After FDA IDE Approval for nPulse Cardiac Ablation Trial - Sahm
Pulse Biosciences Updates Investors on Product Advancements - MSN
Pulse Biosciences, Inc (PLSE) Investor Outlook: Exploring A 44.74% Potential Upside - DirectorsTalk Interviews
Why Pulse Biosciences (PLSE) Is Up 8.0% After FDA Clears Pivotal Atrial Fibrillation Trial - Sahm
Pulse Biosciences holds 2025 annual stockholder meeting - MSN
Pulse Biosciences (NASDAQ:PLSE) Is In A Good Position To Deliver On Growth Plans - Sahm
Can Pulse Biosciences Inc. stock beat market expectations this quarterEarnings Recap Report & Growth Focused Stock Reports - Улправда
What technical signals suggest for Pulse Biosciences Inc. stockSell Signal & AI Driven Price Forecasts - Улправда
Pulse Biosciences announces inducement grants under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Market Pulse: How Aura Biosciences Inc. stock performs in high volatility marketsWall Street Watch & Long-Term Safe Investment Ideas - Улправда
Aug Fed Impact: Can Pulse Biosciences Inc. (6L8) stock deliver double digit returnsQuarterly Growth Report & Free Weekly Chart Analysis and Trade Guides - Улправда
PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial - sharewise.com
How Pulse Biosciences Inc. stock responds to policy changesMarket Risk Summary & Daily Risk Controlled Trade Plans - DonanımHaber
Can Pulse Biosciences Inc. stock resist market sell offs2025 Support & Resistance & Community Verified Trade Signals - DonanımHaber
Finanzdaten der Pulse Biosciences Inc-Aktie (PLSE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pulse Biosciences Inc-Aktie (PLSE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Danahy Kevin Patrick | Chief Commercial Officer |
Oct 02 '25 |
Sale |
18.53 |
4,600 |
85,238 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Option Exercise |
1.53 |
400 |
612 |
43,698 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Sale |
18.49 |
20,000 |
369,800 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Sale |
18.48 |
400 |
7,392 |
43,298 |
| UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Option Exercise |
4.00 |
181,534 |
726,136 |
284,406 |
| UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Option Exercise |
4.00 |
25,000 |
100,000 |
147,872 |
| UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Sale |
16.28 |
25,000 |
407,000 |
122,872 |
| UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Sale |
16.21 |
20,000 |
324,200 |
122,872 |
0.01%
1.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):